Phibro Animal Health said Brazil is moving to a new regulatory regime that will bar the import, manufacturing, marketing and use of performance-enhancing feed additives containing antimicrobials deemed important in human or veterinary medicine, including virginiamycin and bacitracin.
The change comes under Ordinance No. 1617, published April 27, 2026, and will take effect after a 180-day transition period. During that window, companies and customers can continue to use and sell the products under their current labels.
Phibro said it has been working with Brazil’s agriculture ministry and industry groups on the transition. The company said registrations for virginiamycin for therapeutic use in cattle and broiler chickens are in the final stages of review and approval, and it expects those approvals during the transition period.
Phibro also said its bacitracin product in Brazil already carries therapeutic claims.
After the transition period, use of the affected antimicrobials will require a veterinary prescription. To support that shift, Phibro is rolling out Phibrovet, a digital platform for creating, transmitting and managing veterinary prescriptions and prescription history in Brazil.
The company said the 180-day window means the regulatory change is expected to have limited impact on fiscal 2026 results. As a result of these announcements, the company's shares have moved 0.86% on the market, and are now trading at a price of $55.16. For more information, read the company's full 8-K submission here.
